Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Jul 19 04:00PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-0.82 Insider Own0.75% Shs Outstand30.68M Perf Week-6.56%
Market Cap11.44M Forward P/E- EPS next Y-0.47 Insider Trans0.00% Shs Float30.45M Perf Month-26.14%
Income-18.76M PEG- EPS next Q-0.12 Inst Own8.67% Short Float2.60% Perf Quarter-19.09%
Sales0.00M P/S- EPS this Y46.67% Inst Trans-8.56% Short Ratio2.32 Perf Half Y-35.70%
Book/sh1.20 P/B0.31 EPS next Y1.04% ROA-40.38% Short Interest0.79M Perf Year-70.16%
Cash/sh0.35 P/C1.05 EPS next 5Y- ROE-48.17% 52W Range0.30 - 1.80 Perf YTD-52.18%
Dividend Est.- P/FCF- EPS past 5Y26.09% ROI-60.25% 52W High-79.28% Beta1.03
Dividend TTM- Quick Ratio1.34 Sales past 5Y-20.00% Gross Margin- 52W Low23.39% ATR (14)0.05
Dividend Ex-Date- Current Ratio1.34 EPS Y/Y TTM19.92% Oper. Margin0.00% RSI (14)39.37 Volatility8.33% 12.67%
Employees20 Debt/Eq0.01 Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price6.50
Option/ShortYes / Yes LT Debt/Eq0.00 EPS Q/Q38.22% Payout- Rel Volume0.24 Prev Close0.36
Sales Surprise- EPS Surprise26.32% Sales Q/Q- EarningsMay 21 BMO Avg Volume341.57K Price0.37
SMA20-8.51% SMA50-29.93% SMA200-51.83% Trades Volume83,386 Change2.30%
Jul-10-24 07:30AM
Jul-02-24 04:00PM
Jul-01-24 09:00AM
Jun-27-24 07:45AM
Jun-01-24 08:00AM
01:52PM Loading…
May-21-24 01:52PM
Apr-25-24 07:00AM
Mar-28-24 07:00AM
Mar-14-24 07:30AM
Mar-13-24 09:55AM
Mar-05-24 11:52PM
Feb-27-24 07:00AM
Feb-13-24 07:00AM
07:30AM Loading…
Feb-01-24 07:30AM
Dec-20-23 08:05AM
Dec-14-23 06:50AM
Nov-21-23 06:50AM
Nov-02-23 07:00AM
Oct-19-23 03:55PM
Oct-17-23 08:00AM
Oct-06-23 07:50AM
Oct-03-23 07:50AM
Sep-21-23 08:00AM
Aug-22-23 09:29AM
Jul-11-23 08:15AM
May-16-23 04:00PM
Apr-25-23 08:00AM
Apr-19-23 08:15AM
07:00AM Loading…
Apr-18-23 07:00AM
Mar-24-23 07:00AM
Mar-16-23 07:00AM
Feb-14-23 07:01AM
Feb-08-23 07:12AM
Feb-02-23 07:00AM
Jan-03-23 07:00AM
Nov-15-22 07:00AM
Nov-10-22 07:00AM
Nov-08-22 07:53AM
Nov-02-22 07:37AM
Aug-04-22 07:30AM
Jul-14-22 07:30AM
May-27-22 07:15AM
May-18-22 08:18AM
May-12-22 08:13AM
Apr-11-22 07:37AM
Feb-24-22 12:12AM
Feb-09-22 07:00AM
Feb-04-22 07:35AM
Jan-06-22 07:30AM
Dec-09-21 07:30AM
Dec-06-21 07:30AM
Nov-03-21 07:30AM
Oct-26-21 08:27AM
Oct-22-21 06:00AM
Sep-24-21 07:38AM
Sep-13-21 07:00AM
Aug-05-21 08:30AM
Jun-04-21 08:00AM
May-26-21 07:38AM
May-20-21 07:00AM
May-19-21 07:00AM
Apr-23-21 08:00AM
Apr-13-21 08:17AM
Mar-19-21 08:00AM
Mar-11-21 08:02AM
Mar-03-21 07:00AM
Mar-02-21 07:00AM
Jan-18-21 07:41AM
Jan-04-21 09:40AM
Purple Biotech Ltd. is a development stage pharmaceutical company, which engages in drug development. It operates through two segments: Oncology, and Pain & Hypertension. The Oncology segment includes NT219, a therapeutic candidate which is a small molecule that targets two signal transduction pathways which are involved in the development of cancer drug resistance mechanisms, and which is currently in the late pre-clinical stage of development. The Pain & Hypertension segment includes Consensi, a combination drug for the simultaneous treatment of two clinical conditions, pain caused by osteoarthritis and hypertension (high blood pressure), which can be pre-existing or caused by the treatment for osteoarthritis. The company was founded by John Paul Waymack on August 12, 1968 and is headquartered in Rehovot, Israel.